This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix to evaluate sustained-release travoprost for glaucoma, ocular hypertension

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix has begun enrolling the first subjects in a phase 2b clinical trial to evaluate the safety and efficacy of sustained-release travoprost, according to a press release.

Sustained-release travoprost (OTX-TP) is being evaluated for the reduction of elevated IOP in patients with open-angle glaucoma and ocular hypertension.

Eighty patients at 10 clinical sites will be enrolled to determine the safety and efficacy of OTX-TP compared with timolol in the prospective, multicenter, randomized, double-masked, parallel-arm, active controlled study.

Endpoints will include differences in mean IOP between treatment groups at baseline and various time periods during the study.

Previous studies have indicated that OTX-TP can reduce IOP for up to 3 months, a similar finding as timolol administered twice daily, according to the release.